Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071563
Filing Date
2025-05-14
Accepted
2025-05-14 16:51:05
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aktx-20250331.htm   iXBRL 10-Q 2103269
2 EX-10.5 aktx-ex10_5.htm EX-10.5 110481
3 EX-31.1 aktx-ex31_1.htm EX-31.1 15720
4 EX-31.2 aktx-ex31_2.htm EX-31.2 15708
5 EX-32.1 aktx-ex32_1.htm EX-32.1 11846
6 EX-32.2 aktx-ex32_2.htm EX-32.2 11369
  Complete submission text file 0000950170-25-071563.txt   10672402

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20250331.xsd EX-101.SCH 1821772
83 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20250331_htm.xml XML 1927504
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 10-Q | Act: 34 | File No.: 001-36288 | Film No.: 25946704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)